Description
Human Apolipoprotein CI (Apo CI) |P11
Concentration: | 1 mg / ml, determined by the Lowry method |
Source: | From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens. |
Purification: | After series ultracentrifugations, Very Low Density Lipoprotein (VLDL) is isolated from human plasma. Apo CI is purified from delipidated VLDL, followed by gel-filtration and DEAE-Sepharcyl chromatography. |
Purity: | ≥ 98% by SDS-PAGE |
Buffer: | In 75 mM Sodium Phosphate, 75 m M NaCl, 0.02 % NaN3, 1 mM EDTA, p H 7.4. |
Storage: | -20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing. |
*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
IMPORTANCE
ApoCI contains 57 amino acid residues and the m.w. is 6.6 kDa (Jackson et al., 1974).
ApoCI has been found to activate LCAT (Liu and Subbaiah 1993). Apo CI is an inhibitor of lipoprotein binding to the LDL receptor, LDL receptor-related protein, and VLDL receptor. Apo CI is also an inhibitor of the plasma cholesteryl ester transfer protein and of fatty acid uptake into tissues (Shachter, 2001). This inhibition role can potentially regulate several lipase enzymes (Poensgen, 1990, Conde-Knape et al., 2002; Berbee et al., 2005.)